Akebia Therapeutics (AKBA) Asset Writedowns and Impairment (2019 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Asset Writedowns and Impairment of $3.2 million for Q1 2026, up 1873.01% year-over-year from $163000.0 in Q1 2025, and up 598.6% quarter-over-quarter from -$645000.0 in Q4 2025.
Akebia Therapeutics (AKBA) Asset Writedowns and Impairment (2019 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Asset Writedowns and Impairment for 8 consecutive years, with $3.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Asset Writedowns and Impairment rose 1873.01% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $3.1 million (up 2203.42% YoY), while the FY2024 annual figure was $294000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment improved to $3.2 million in Q1 2026 per AKBA's latest filing, from -$645000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $5.3 million in Q1 2022 and bottomed at -$9.6 million in Q4 2022.
- Historically, Asset Writedowns and Impairment has averaged $245562.5 across 5 years, with a median of $500000.0 in 2024.
- Annual changes were most pronounced in 2023 — Asset Writedowns and Impairment tumbled 93.68% — and 2026, when it soared 1873.01%.
- Akebia Therapeutics' Asset Writedowns and Impairment stood at -$9.6 million in 2022, then jumped by 86.17% to -$1.3 million in 2023, then tumbled by 58.93% to -$2.1 million in 2024, then soared by 69.42% to -$645000.0 in 2025, then surged by 598.6% to $3.2 million in 2026.
- Business Quant data shows AKBA's Asset Writedowns and Impairment at $3.2 million in Q1 2026, -$645000.0 in Q4 2025, and $500000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.70 Mn |
| Jun 30, 2026 | 1.70 Mn |
| Mar 31, 2026 | 3.22 Mn |
| Mar 31, 2026 | 3.22 Mn |
| Dec 31, 2025 | -645,000.00 |
| Dec 31, 2025 | -645,000.00 |
| Sep 30, 2025 | 500,000.00 |
| Sep 30, 2025 | 500,000.00 |
| Mar 31, 2025 | 163,000.00 |
| Mar 31, 2025 | 163,000.00 |
| Dec 31, 2024 | -2.11 Mn |
| Dec 31, 2024 | -2.11 Mn |
| Sep 30, 2024 | 1.30 Mn |
| Sep 30, 2024 | 1.30 Mn |
| Jun 30, 2024 | 500,000.00 |
| Jun 30, 2024 | 500,000.00 |
| Mar 31, 2024 | 590,000.00 |
| Mar 31, 2024 | 590,000.00 |
| Dec 31, 2023 | -1.33 Mn |
| Dec 31, 2023 | -1.33 Mn |